Abstract
The aim of this study was to screen for acetylcholinesterase (AChE) inhibitors from a large chemical library of commercially available compounds. For this purpose, the Ellmans reaction based assay was miniaturized into 384-well plate format, and two modifications of the kinetic protocol were studied with the aim of developing a rapid screening platform that could ensure high efficiency in finding true hits. It was proven that when starting the kinetic reaction by addition of the substrate, better assay performance was achieved and more practical benefits obtained. Using the optimized automated protocol, a chemical library of 56,320 compounds was screened. A total of 350 positive hits were identified and their IC50 calculated. Three highly active compounds were identified with IC50 values close or even lower to physostigmine ( < 0.1 μM). The activity towards butyrylcholinesterase (BChE) of these three most active hits was also evaluated. The most active hit (IC50(AChE) = 0.019 μM), was identified as a new inhibitor, belonging to ChemDiv chemical library: (N-[3-(3,5-dimethyl-1-piperidinyl)propyl]-5-ethyl-2-methyl-8-oxo-thieno[2,3:4,5]pyrrolo[1,2-d] [1,2,4] triazine- 7(8H)-acetamid), with no other biological activities reported until now. The interactions of this hit with both cholinesterases were further analyzed using computational docking studies. To our knowledge, this is the largest published screening campaign of commercially available compounds that has focused on finding new AChE inhibitors. The miniaturized 384-well plate format of the Ellmans method was proven to be robust and to perform reliably.
Keywords: Acetylcholinesterase, butyrylcholinesterase, inhibition, high-throughput screening, miniaturization, Ellman's method
Combinatorial Chemistry & High Throughput Screening
Title: Miniaturization and Validation of the Ellmans Reaction Based Acetylcholinesterase Inhibitory Assay into 384-Well Plate Format and Screening of a Chemical Library
Volume: 13 Issue: 3
Author(s): Paivi P. Jarvinen, Adyary Fallarero, Shikhar Gupta, Gobi C. Mohan, Annele I. Hatakka and Pia M. Vuorela
Affiliation:
Keywords: Acetylcholinesterase, butyrylcholinesterase, inhibition, high-throughput screening, miniaturization, Ellman's method
Abstract: The aim of this study was to screen for acetylcholinesterase (AChE) inhibitors from a large chemical library of commercially available compounds. For this purpose, the Ellmans reaction based assay was miniaturized into 384-well plate format, and two modifications of the kinetic protocol were studied with the aim of developing a rapid screening platform that could ensure high efficiency in finding true hits. It was proven that when starting the kinetic reaction by addition of the substrate, better assay performance was achieved and more practical benefits obtained. Using the optimized automated protocol, a chemical library of 56,320 compounds was screened. A total of 350 positive hits were identified and their IC50 calculated. Three highly active compounds were identified with IC50 values close or even lower to physostigmine ( < 0.1 μM). The activity towards butyrylcholinesterase (BChE) of these three most active hits was also evaluated. The most active hit (IC50(AChE) = 0.019 μM), was identified as a new inhibitor, belonging to ChemDiv chemical library: (N-[3-(3,5-dimethyl-1-piperidinyl)propyl]-5-ethyl-2-methyl-8-oxo-thieno[2,3:4,5]pyrrolo[1,2-d] [1,2,4] triazine- 7(8H)-acetamid), with no other biological activities reported until now. The interactions of this hit with both cholinesterases were further analyzed using computational docking studies. To our knowledge, this is the largest published screening campaign of commercially available compounds that has focused on finding new AChE inhibitors. The miniaturized 384-well plate format of the Ellmans method was proven to be robust and to perform reliably.
Export Options
About this article
Cite this article as:
Jarvinen P. Paivi, Fallarero Adyary, Gupta Shikhar, Mohan C. Gobi, Hatakka I. Annele and Vuorela M. Pia, Miniaturization and Validation of the Ellmans Reaction Based Acetylcholinesterase Inhibitory Assay into 384-Well Plate Format and Screening of a Chemical Library, Combinatorial Chemistry & High Throughput Screening 2010; 13 (3) . https://dx.doi.org/10.2174/138620710790980559
DOI https://dx.doi.org/10.2174/138620710790980559 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Neuroscience of Exercise: Association Among Neurobiological Mechanisms and Mental Health
CNS & Neurological Disorders - Drug Targets Intracellular Signaling and Approaches to the Treatment of Schizophrenia and Associated Cognitive Impairment
Current Pharmaceutical Design The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design <i>Cannabis Sativa</i> L. Flower and Bud Extracts Inhibited <i>In vitro</i> Cholinesterases and β-Secretase Enzymes Activities: Possible Mechanisms of Cannabis Use in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems
Current Drug Targets GABAA Receptor Subtype Selective Cognition Enhancers
Current Drug Targets - CNS & Neurological Disorders Older Australians: Structural barriers to learning in later life
Current Aging Science The Modulation of Beneficial and/or Harmful Effects of Free Oxygen Radicals in the Context of Molecular Mechanisms Regarding Drug – PART I
Current Topics in Medicinal Chemistry Dance for People with Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Pharmacological Approaches for Treatment-resistant Bipolar Disorder
Current Neuropharmacology Protective Effects of Chronic Green Tea Consumption on Age-related Neurodegeneration
Current Pharmaceutical Design Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology